A study of erythropoietin use for myelodysplastic syndrome;Estudio de utilización de eritropoyetina en el síndrome mielodisplásico

Farmacia Hospitalaria

Volumn 28, Issue 6, 2004, Pages 395-401

  Márquez Saavedra, Esther ^a   Artacho Criado, S ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Anemia; Drug use study; Erythropoietin; Myelodysplastic syndrome

Indexed keywords

ERYTHROPOIETIN;

AGED; ANAMNESIS; ANEMIA; ARTICLE; DATA BASE; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; FOLLOW UP; HOSPITAL PHARMACY; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; OUTPATIENT DEPARTMENT; PUBLICATION; RETROSPECTIVE STUDY;

AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HEMATOLOGIC TESTS; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 13444291632     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Sanz GF, Sanz MA, Vallespi T. Etiopathogeny, prognosis and therapy of myelodysplastic syndromes. Hematol Cell Ther 1997; 39: 277-94.
2. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120: 187-200.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-99.
4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88.
5. Kasper C, Zahner J, Sayer HG. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol 2002; 128: 497-502.
6. Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 1998; 83: 910-35.
7. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, et al. Evidence and consensus based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002; 87: 1286-306.
8. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67-71.
9. Italian Cooperative Study Group for EPO in myelodysplastic syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998; 103: 1070-4.
10. Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997; 99: 344-51.
11. Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, J̊ulia A, et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a sub-group of responders. Haematologica 1999; 84: 1058-64.
12. Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 2002; 68: 180-6.
13. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037-46.
14. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de Especialidades Farmacéuticas, 2003.
15. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68-75.
16. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-4.
17. Rodríguez JN, Diéguez JC, Muñiz R, Martino ML, Fernández-Jurado A, Amian A, et al. Eritropoyetina recombinante humana en el tratamiento de la anemia de los síndromes mielodisplásicos. Estudio metaanalítico. Sangre 1994; 39: 435-9.
18. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87: 4076-81.